Michael DeMane - Nevro Corp Lead Independent Director
| NVRO Stock | USD 5.77 0.01 0.17% |
Director
Mr. Michael F. DeMane is Lead Director of the company. he was Executive Chairman of the Board of the Company. Mr. DeMane has served as our Chairman of the Board and Chief Executive Officer. Mr. DeMane has served as the board of directors of several private companies since 2009, as well as on the board of directors of eReserach Technology, Inc., a public company specializing in clinical services and customizable medical devices, from July 2008 to April 2012. From March 2009 to June 2010, Mr. DeMane served as a Senior Advisor to Thomas, McNerney Partners, a healthcare venture firm. Mr. DeMane served as the Chief Operating Officer of Medtronic, Inc. from August 2007 to April 2008. Prior to his COO role, Mr. DeMane served at Medtronic Inc. as Senior Vice President from May 2007 to August 2007, Senior Vice President and President Europe, Canada, Latin America and Emerging Markets from August 2005 to May 2007, Senior Vice President and President Spinal, ENT and Navigation from February 2002 to August 2005, and President, Spinal from January 2000 to February 2002. Prior to that, he was President at Interbody Technologies, a division of Medtronic Sofamor Danek, Inc., from June 1998 to December 1999. From April 1996 to June 1998, Mr. DeMane served at Smith Nephew Pty. Ltd. as Managing Director, Australia and New Zealand, after a series of research and development and general management positions with Smith Nephew Inc since 2019.
| Age | 63 |
| Tenure | 6 years |
| Address | 1800 Bridge Parkway, Redwood City, CA, United States, 94065 |
| Phone | 650 251 0005 |
| Web | https://nevro.com |
Michael DeMane Latest Insider Activity
Tracking and analyzing the buying and selling activities of Michael DeMane against Nevro Corp stock is an integral part of due diligence when investing in Nevro Corp. Michael DeMane insider activity provides valuable insight into whether Nevro Corp is net buyers or sellers over its current business cycle. Note, Nevro Corp insiders must abide by specific rules, including filing SEC forms every time they buy or sell Nevro Corp'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Michael DeMane over three months ago Acquisition by Michael DeMane of 4695 shares of Nevro Corp subject to Rule 16b-3 |
Nevro Corp Management Efficiency
The company has return on total asset (ROA) of (0.0995) % which means that it has lost $0.0995 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4329) %, meaning that it created substantial loss on money invested by shareholders. Nevro Corp's management efficiency ratios could be used to measure how well Nevro Corp manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of March 2025, Return On Tangible Assets is likely to drop to -0.22. In addition to that, Return On Capital Employed is likely to drop to -0.29. At this time, Nevro Corp's Non Current Assets Total are very stable compared to the past year. As of the 22nd of March 2025, Intangible Assets is likely to grow to about 25.6 M, while Total Assets are likely to drop about 473.1 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| William Summers | Integer Holdings Corp | 70 | |
| Charles Farkas | CONMED | 68 | |
| Martin Maxwell | Integer Holdings Corp | 62 | |
| Kristina Wright | Paragon 28 | 47 | |
| Jean Hobby | Integer Holdings Corp | 60 | |
| Gilbert Kliman | Glaukos Corp | 61 | |
| Mark Foley | Glaukos Corp | 55 | |
| James Hinrichs | Integer Holdings Corp | 53 | |
| David Hoffmeister | Glaukos Corp | 66 | |
| Filippo Passerini | Integer Holdings Corp | 63 | |
| Brian Concannon | CONMED | 62 | |
| Cheryl Capps | Integer Holdings Corp | 59 | |
| Marc Stapley | Glaukos Corp | 50 | |
| John Workman | CONMED | 69 | |
| Fred Hite | Orthopediatrics Corp | 57 | |
| Martha Aronson | CONMED | 53 | |
| David Bronson | CONMED | 67 | |
| Sheila Antrum | Integer Holdings Corp | 62 | |
| Jerome Lande | CONMED | 45 | |
| Donald Spence | Integer Holdings Corp | 67 | |
| Aimee Weisner | Glaukos Corp | 51 | |
Management Performance
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.0995 |
Nevro Corp Leadership Team
Elected by the shareholders, the Nevro Corp's board of directors comprises two types of representatives: Nevro Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nevro. The board's role is to monitor Nevro Corp's management team and ensure that shareholders' interests are well served. Nevro Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nevro Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Julie Dewey, Vice President - Investor Relations and Corporate Communications | ||
| Elizabeth Weatherman, Independent Director | ||
| Brad Vale, Independent Director | ||
| Donald Middlebrook, Vice President - Clinical, Regulatory and Quality | ||
| Christopher Christoforou, Vice President - Research and Development | ||
| Kevin OBoyle, Independent Director | ||
| Meredith Vornholt, Vice Marketing | ||
| Kashif JD, Senior Officer | ||
| Peter Socarras, General VP | ||
| Shawn McCormick, Independent Director | ||
| David Caraway, Chief Medical Officer | ||
| Christofer Christoforou, Senior Operations | ||
| DKeith Grossman, Chairman of the Board, President, Chief Executive Officer | ||
| Patrick Schmitz, Vice President - Operations | ||
| Richard Carter, Chief Officer | ||
| Sridhar Kosaraju, Director | ||
| Frank Fischer, Independent Director | ||
| Michael DeMane, Lead Independent Director | ||
| Kevin Thornal, CEO President | ||
| Roderick MacLeod, Chief Financial Officer | ||
| Greg Siller, Senior Officer | ||
| Shana MBA, Senior Officer | ||
| Michael Carter, Vice President - Global Sales | ||
| D Grossman, Chairman of the Board, President, Chief Executive Officer | ||
| Susan Siegel, Independent Director | ||
| Karen Prange, Independent Director | ||
| Angeline McCabe, Vice Communications | ||
| Kashif Rashid, Chief Compliance Officer, General Counsel, Corporate Secretary | ||
| Geeta Kaveti, VP Officer | ||
| Niamh Pellegrini, Chief Commercial Officer | ||
| Lori Ciano, Chief Human Resource Officer | ||
| David MD, Senior Officer | ||
| Jon Shear, Senior Development |
Nevro Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nevro Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.0995 | ||||
| Profit Margin | (0.28) % | ||||
| Operating Margin | (0.22) % | ||||
| Current Valuation | 180.04 M | ||||
| Shares Outstanding | 38.37 M | ||||
| Shares Owned By Insiders | 2.87 % | ||||
| Shares Owned By Institutions | 97.13 % | ||||
| Number Of Shares Shorted | 1.82 M | ||||
| Price To Earning | (63.38) X |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nevro Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Nevro Stock, please use our How to Invest in Nevro Corp guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nevro Corp. If investors know Nevro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nevro Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.06) | Revenue Per Share | Quarterly Revenue Growth (0.09) | Return On Assets | Return On Equity |
The market value of Nevro Corp is measured differently than its book value, which is the value of Nevro that is recorded on the company's balance sheet. Investors also form their own opinion of Nevro Corp's value that differs from its market value or its book value, called intrinsic value, which is Nevro Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nevro Corp's market value can be influenced by many factors that don't directly affect Nevro Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nevro Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Nevro Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nevro Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.